The companies are testing the cancer vaccine in combination with Merck's blockbuster drug, Keytruda. Moderna stock surged ...

MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-stage non ...

Moderna is working on individualized neoantigen therapy, which tailors treatment to each patient's individual cancer. The company is working with Merck and its blockbuster cancer drug Keytruda on ...

The vaccine also cut the risk of recurrence or death by 44%, versus Keytruda alone. Moderna has a solid pipeline of around 45 products in development, and nearly a quarter of them are expected to ...

Moderna's (NASDAQ: MRNA ... The reason why I mention Merck is that its cancer immunotherapy, Keytruda, ranked as the world's best-selling drug last year with sales of $25 billion.

This is a way for Moderna to take a seat at the table of personalized medicine. The company’s most advanced candidate is V940-Keytruda, which entered Phase III trials in 2024. The vaccine is ...

Moderna, Inc. (NASDAQ ... an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, as adjuvant treatment for ...